Documentation scienceplus.abes.fr version Bêta

À propos de : Falciparum malaria semi-resistant to clindamycin.        

AttributsValeurs
type
Is Part Of
Subject
Title
  • Falciparum malaria semi-resistant to clindamycin.
has manifestation of work
related by
Abstract
  • Clindamycin, a semi-synthetic antibiotic of the lincomycin family, at a dose of 450 mg eight-hourly for three days in adults cured five out of 10 patients moderately ill with chloroquine-resistant falciparum malaria. Combination therapy with full-dose quinine and clindamycin for three days cured all four patients so treated who were followed up, and with half dosage three out of five patients were cured. Both combinations, however, caused upper gastrointestinal toxicity and appeared to potentiate both toxicity and possibly antimalarial efficacy. Colitis due to clindamycin was not observed. Sequential therapy was not toxic and could be useful in patients who have relapsed after more conventional treatment.
article type
is part of this journal
PubMed ID
  • 1093609



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata